Asthma BREATHE Grand Rounds Enduring Simulcast
Immunological Targeting Approach for the Management of Moderate-to-Severe Asthma
Nicola A. Hanania, MD, MS, FRCP(C), FCCP, FACP, FERS, ATSF (PROGRAM CHAIR)
Associate Professor of Medicine,
Director, Airway Clinical Research Center
Pulmonary, Critical Care and Sleep Medicine
This program will review current and emerging therapies for the management of moderate-to-severe uncontrolled asthma.
This CME initiative is designed to meet the educational needs of pulmonologists, allergists, immunologists, and otolaryngologists involved in the healthcare of patients with moderate-to-severe uncontrolled asthma.
Upon the completion of this program, attendees should be able to:
- Review the molecular basis for the pathophysiology of moderate-to-severe asthma and the corresponding targeted biologic therapies
- Describe the current medical committee guidelines and their application in clinical practice for the management of patients with moderate-to-severe asthma
- Discuss the clinical trials data of biologic therapies as add-on treatments in the maintenance setting for patients with moderate-to-severe asthma
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of patients with moderate-to-severe asthma.
Credits: 1.0 ANCC Contact Hour.
CNE Accreditation Statement: Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
|Nicola A. Hanania, MD, MS, FRCP(C), FCCP, FACP, FERS, ATSF
|Served on the Speakers Bureau for AstraZeneca and worked as a consultant for GlaxoSmithKline, Boehringer Ingleheim, Genentech, Novartis, Sanofi, Regeneron and AstraZeneca, Teva and Amgen. He has also done contracted research for GlaxoSmithKline, Boehringer Ingleheim, Sanofi, Genentech, Novartis and Gossamer|
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Chris Drury, MA, MS, MBA, Medical Director for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Lauren Bartunek, Program Manager for Med Learning Group, has nothing to disclose.
Marissa Mays-Verman, Program Manager for Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures.
- Participate in the enduring activity.
- Complete the online post-test and evaluation.
You will receive your certificate as a downloadable file.
Med Learning Group makes every effort to develop CME activities that are science based.
This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at firstname.lastname@example.org
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at email@example.com
Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
Addressing the Type 2 Inflammation Signature Through the Management of CRSwNP
Stella Lee, MD
Department of Otolaryngology
Director, Division of Sino-nasal Disorders and Allergy
University of Pennsylvania Medical Center
RELEASE DATE: January 6, 2021
EXPIRATION DATE: January 6, 2022